Skip to content
LGND·Nasdaq·US

Ligand Pharmaceuticals

Ligand Pharmaceuticals is a biopharmaceutical royalty company that invests in and structures royalty interests in mid- to late-stage development and commercial biopharmaceutical products. It also operates two royalty-generating platform technologies, Captisol and NITRICIL. Its revenue comes primarily from royalties on partners' product sales, supplemented by Captisol material sales and contract revenue from license fees and milestone payments.

Source: SEC 10-K Feb 27, 2026

Thematic Position

LGND

Relationship Groups

Customers4
Partners5
Licensing13
Competitors1

Relationship details are part of the Pro plan.

Recent Discoveries

Recent discoveries are part of the Pro plan.

Ended Relationships

5 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

armed conflictsanction
U.S. and foreign government actions over Russia-Ukraine conflict may limit patent prosecution and maintenance in Russia
SEC 10-KFeb 27, 2026

The full regulatory passage is part of the Pro plan.

1 more · Regulatory and geopolitical insights are part of the Pro plan.